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Background and purpose: Erectile dysfunction is a common consequence of external beam radiotherapy
(EBRT) for prostate cancer. The addition of neo-adjuvant androgen deprivation (NAD) has an indetermi-
nate additive effect. We examined the long-term effect on erectile function (EF) of two durations
(4 months: arm 1 and 8 months: arm 2) of NAD prior to radiation (RT) for patients with localised prostate
cancer from the Irish Clinical Oncology Research Group (ICORG 97-01) 4- versus 8-month trial. In this
study we aimed to (1) analyse the overall effect on EF of NAD in an EBRT population, (2) compare the
probability of retained EF over time in an EBRT population treated with either 4 or 8 months of NAD
and (3) identify any variables such as risk group and age which may have an additive detrimental effect.
This analysis provides unique long term follow up data.
Materials and methods: From 1997 to 2001, 276 patients with adenocarcinoma of the prostate were ran-
domised to 4 or 8 months of NAD before RT. EF data were recorded at baseline and at each follow-up visit
by physician directed questions, using a 4-point grading system.
Results: Two hundred and thirty patients were included in the analysis of EF and were followed for a
median of 80 months. One hundred and forty-one patients had EF at baseline. Neo-adjuvant androgen
deprivation in addition to radiation therapy caused a signiﬁcant reduction in EF. The most signiﬁcant
reduction in EF happens within the ﬁrst year. The median time to grade 3–4 EF toxicity was 14.6 months,
17.6 months in arm 1 and 13.7 in arm 2. Freedom from late EF toxicity did not differ signiﬁcantly between
arms, overall or at 5 years (n = 141). The cumulative probability of EF preservation at 5 years was 28%
(22–34) in arm 1 and 24% (19–30) in arm 2. Age was a signiﬁcant predictor of post-treatment EF.
Conclusions: The ﬁrst year post ADT and EBRT poses the greatest risk to sexual function and a continued
decline may be expected. However, 26% of men can expect to retain sexual function at 5 years.
 2012 Elsevier Ireland Ltd.Open access under CC BY-NC-ND license.
Radiotherapy and Oncology 104 (2012) 96–102In 1997, the Irish Clinical Oncology Research Group initiated a
randomised clinical trial (ICORG 97-01) investigating the effective-
ness of different durations of neo-adjuvant androgen deprivation
(NAD) using a combination of LHRH agonist triptorelin (Decapep-
tyl) and oral ﬂutamide (Drogenil) anti-androgen tablets prior
to deﬁnitive external beam radiation therapy (EBRT) for locally ad-
vanced prostate carcinoma. The primary endpoint was freedom
from biochemical relapse. One of the secondary objectives was to
evaluate toxicities including erectile function (EF). In this study
we aimed to (1) analyse the overall effect on EF of NAD in an EBRT
population, (2) compare the probability of retained EF over time in
an EBRT population treated with either 4 or 8 months of NAD ander CC BY-NC-ND license.(3) identify any variables such as risk group and age which may
have an additive detrimental effect.
Erectile dysfunction (ED) after deﬁnitive RT for prostate cancer
has been previously described. In one study by Turner et al. [1] it
was reported that 38% of men whose EF was adequate before treat-
ment had ED at 12 months, and this percentage increased to 59% at
24 months. Published studies report a wide degree of variation in
the incidence of ED post EBRT. A review by Incrocci et al. [2] noted
published rates of ED varying from 6% to 84% post EBRT alone. A
meta-analysis of 54 studies where the pre-treatment functioning
of subjects was known suggests that maintenance of EF varies
widely [3].
Additionally, we know that androgen deprivation therapy (ADT)
alone causes erectile dysfunction. For example, Potosky reported
an incidence of ED of 80% in men receiving androgen deprivation
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men receiving no treatment [4].
Despite the increasing use of bimodality treatment, the effect of
the combination NAD and EBRT on erectile function is less well re-
ported in the literature than the effects of either modality alone.
The need for further studies with ‘‘primary outcomes of overall
and disease speciﬁc survival, disease progression and adverse ef-
fects including long term consequences of prolonged androgen
deprivation including quality of life’’ was recognised by Shelley
et al. during a review of randomised trials using neo-adjuvant
androgen deprivation [5]. The impact of NAD on ultimate recovery
of sexual function after the combined treatment is not known nor
is the speciﬁc effect of duration of NAD on EF. Age, diabetes, coro-
nary artery disease, etc. are other confounding factors. In addition
long term follow up data are not widely available and there are few
studies following patients who have detailed pre-treatment EF
data. The possibility of ED frequently causes a high level of anxiety
for the patient and given the variability of published data it is dif-
ﬁcult to adequately counsel an individual about his particular risk.
This paper attempts to address some of these previously unan-
swered questions and to examine other pre-treatment factors for
their association with the development of ED.Methods
The 4- versus 8-month trial (ICORG 97-01) was a randomised
trial that accrued 276 patients with clinically localised prostate
cancer between February 1997 and December 2001. This trial com-
pared the effectiveness of two durations of NAD before radical
external beam RT (70 Gy) in subjects with T1 to T4 N0 M0 prostate
cancer. Patients were randomly assigned to receive 4 or 8 months
of NAD consisting of a combination of LHRH agonist triptorelin
(Decapeptyl) and oral ﬂutamide (Drogenil) anti-androgen tab-
lets. The primary endpoint was freedom from biochemical relapse.
The design, objectives, patient eligibility criteria, treatment meth-
ods and statistical considerations have been reported previously
[6].
Eligible patients were node negative and had no metastases
with one or more of: PSA >20 ng/mL, Gleason score P7, and stage
T3 or more. The intermediate-risk stratum had one risk factor and
the high-risk stratum had 2 or more risk factors (protocol risk
stratiﬁcation) [7].
The patients were required to have a performance status ofP60
on the Karnofsky scale. Evaluation for distant metastases included
history and physical examination, FBC, screening proﬁle including
liver function tests, CXR, and bone scan. Any abnormalities on bone
scan were investigated. A CT pelvis described nodal status on all
patients. Suspicious nodes were histologically proven to be benign.
Patients were excluded if they had prior treatment for prostate
cancer other than by transurethral resection of the prostate. Pa-
tients with a bilateral orchidectomy or prior hormone therapy
were excluded. Other criteria for exclusion included previous
malignancies (other than non-melanoma skin cancer) or medical
illnesses severe enough to preclude a radical approach to
treatment.Radiation therapy
Three-dimensional conformal RT (3-DCRT) was used in 97% of
patients (70 Gy in 35 fractions). Only these patients are analysed
for EF in this paper.
Patients were positioned supine and underwent CT planning
using 0.5 cm slices. The rectum and bladder were delineated with
an external contour only. The target volume was generated by
placing a 1 cm margin around the entire prostate and seminalvesicles. This margin was reduced to 0.5 cm in the region of the
anterior rectal wall. Treatment was prescribed to an isodose that
completely encompassed the target. The maximum permitted hot
spot within the target volume was 110%. Dose volume constraints
were as follows; no part of the rectum should receive >74 Gy, not
more than 30% of the rectum should receive 100% of the dose,
not more than 50% of the bladder should receive 100% of the dose.
Multiple ﬁelds with customised blocking were used. If necessary a
cone down was performed after 50 Gy (excluding the superior por-
tions of the seminal vesicles from the target volume) to limit the
dose to small bowel to 50 Gy.Neo-adjuvant androgen deprivation therapy
Patients were randomised according to protocol risk stratiﬁca-
tion to receive either 4 or 8 months of NAD prior to external beam
RT (EBRT). NAD consisted of monthly intra muscular injections of
the LHRH agonist triptorelin (Decapeptyl) 3.75 mg once monthly
and oral ﬂutamide (Drogenil) anti-androgen tablets (250 mg 3
times daily). The RT was to begin within 1 month of the end of ADT.
Evaluation during study and follow-up
A pre-inclusion evaluation took place at Visit 1 after which the
patient was randomised according to disease stratiﬁcation to re-
ceive either 4 or 8 injections of the LHRH agonist Triptorelin
(‘‘Decapeptyl 1-month’’). Baseline toxicity/assessment sheets were
completed. Acute and chronic toxicity was graded according to the
criteria of the RTOG–EORTC criteria [8] by way of physician direc-
ted questionnaire. Patients were evaluated for toxicity every week
during RT. Follow-up was three-monthly and included history, rec-
tal examination, PSA, and toxicity assessment. Treatment failure
was noted if there was clinical evidence of local or distant recur-
rence, if salvage ADT was started, or if there was a biochemical fail-
ure (BF).
EF was similarly recorded at baseline and at each follow-up vis-
it, using a 4-point grading system (1 – fully potent/ejaculates, 2 –
able to have an erection but not able to ejaculate, 3 – able to have
a partial erection, 4 – none). These grades were applied regardless
of whether or not a patient used ED aids (Sildenaﬁl citrate (Via-
gra), Tadalaﬁl (Cialis) or Vardenaﬁl (Levitra)). ED included
any patient who noted a decrease in EF from grades 1–2 to grades
3–4 after treatment. For most of the analyses, EF grades were col-
lapsed into two categories i.e. grades 1–2 (sufﬁcient for penetra-
tion) and grades 3–4 (insufﬁcient for penetration).Statistical analysis
Of the 276 patients, 46 were excluded from this analysis, leav-
ing 230 evaluable patients. Five patients were excluded because
they received NAD but no RT; 12 were treated in another centre
and no ED data were available for them; 1 patient refused all treat-
ment; 2 patients from the 4-month arm were excluded as they
continued to receive AD after 4-months and RT was delayed; 1 pa-
tient died shortly after the end of RT; 2 patient had no initial EF
assessment recorded, 3 patients were prescribed salvage hormones
just before or soon after the end of RT; 16 more patients were
either lost to follow-up or EF data were not recorded and 4 patients
were excluded because they received 66 Gy. One patient random-
ised to receive 8 months of NAD received 4 months but was ana-
lysed on an intention to treat basis (Fig. 1).
Late complications, including ED, were deﬁned as those docu-
mented at least 90 days after the last radiation treatment [9]. The
worst severity toxicity documented was considered the ﬁnal toxic-
ity, even if the complication later resolved [9]. Pre-treatment clin-
ical characteristics were compared between subjects treated with
4 versus 8 months of NAD using the Mann–Whitney test and the
e 
276 randomised 
137 assigned 4 month 139 assigned 8 month 
2 excluded as HT 
continued after 4 
months and RT delayed 
8 excluded: treated 
in another centre 
(& no data). 
5 excluded: 4 treated in 
another centre (& no data), 
1 refused all treatment.  
1 excluded as patient 
had no RT  
109 in analysis of 
late EF toxicity 
121 in analysis of 
late EF toxicity 
4 excluded: 2 died before 
RT and 2 had no RT for 
other reasons  
4 excluded: 1 patient died 
(MI) within 4 days of the 
end of RT and 3 
recommenced HT just 
before or soon after the 
end of RT 
9 excluded: no late EF 
toxicity data (1 died < 6 
months after end RT) and 1 
had no initial EF recorded 
9 excluded: 8 had no late 
EF toxicity data and 1 
had no initial EF recorded 
4 excluded as patients 
received 66Gy  
Fig. 1. Randomised trial ICORG 97-01 (1997–2001). Four month neo-adjuvant hormone therapy (arm 1) versus 8 months (arm 2) prior to radiation. N0 M0. Participant ﬂow.
98 Erectile function and duration of neo-adjuvant hormone therapy for prostate cancerChi-square test. The Wilcoxon signed-rank test was used to evalu-
ate the signiﬁcance of change in EF from baseline [10]. The Fried-
man test was used to evaluate the signiﬁcance of change in EF
scores across three or more post-treatment time points.
EF survival times (freedom from late EF toxicity grades 3–4)
were calculated from the last day of RT to the date of ED (grades
3–4), date of salvage hormones or date of last assessment of EF.
The date of the event was taken as the date of the ﬁrst documen-
tation of the highest/worst grade for each patient.
A subgroup comparison of the proportions of patients who were
not prescribed salvage hormones because of biochemical or clinical
failure, in each treatment arm, at speciﬁc times after completion of
RT was made. For this analysis EF survival times were calculated
from the last day of RT to the ﬁrst date (starting 90 days after
RT) of ED (grades 3–4) or date of last assessment of EF.
Survival time to EF toxicity probabilities at (or exceeding) spe-
ciﬁc late grades, was calculated using the Kaplan–Meier method
[11] i.e. survival times to erectile dysfunction. Survival functions
were compared using the log-rank test. The Cox proportional haz-
ards model [12] was used to assess the independent impact of all
potentially important explanatory variables (including treatment
arm and age) on preserved EF.
All statistical tests were two-sided and assessed for signiﬁcance
at the 0.05 level. However, owing to the multiple comparisons of EF
toxicity reported here (a secondary outcome measure of the main
trial) a p-value <0.01 is taken as statistically signiﬁcant for thevarious statistical tests (excluding that for the Cox Regression).
SPSS statistical software version 18.0 (SPSS, Chicago, IL) was used
for all analyses.
Results
As previously published, no signiﬁcant difference was observed
in biochemical disease free survival, prostate cancer speciﬁc sur-
vival, or overall survival between the 4- and 8-month arms [6].
Data for 230 patients were analysed for late EF. The median age
was 67 years. Fifty-four percent of patients reported initial EF
grade 1, 7% reported grade 2, and 9% and 30% reported grades 3
and 4 respectively.
One hundred and forty-one patients (61%) had initial EF grades
1–2 (sufﬁcient for penetration) and formed the main focus for our
analysis. The median age for these 141 patients was 66 years. Ini-
tial EF was graded as 1 in 125 patients (89%) and as 2 in 16 patients
(11%). The characteristics of these patients showed good balance
between the treatment arms with no statistically signiﬁcant differ-
ences except for PSA group (Table 1). Late EF was recorded a med-
ian of 14 times per patient (range 1–25).
The median follow-up time (n = 141) from the end of RT to the
last EF assessment, for patients was 86 months, ranging from 4 to
141 months. One hundred and twenty patients (85%) were
followed for >3 years. There was a longer follow up in the 4 month
arm compared to the 8 month arm (median = 92 versus
Table 1
Randomised trial ICORG 97-01. Four month neo-adjuvant hormone therapy (arm 1) versus 8 months (arm 2) prior to radiation. N0 M0. Pre-treatment characteristics by arm.a
All evaluable Patients with initial grades 1–2
4 Months 8 Months 4 Months 8 Months Mann–Whitney or v2 rest
(n = 109) (n = 121) (n = 62) (n = 79) p
Age (years) 0.517
Mean 66.0 65.6 64.5 63.8
Median 67.0 67.0 66.0 65.0
Age group 0.099
<65 18 (16%) 28 (23%) 21 (26%) 38 (30%)
65–69 42 (39%) 41 (34%) 34 (40%) 29 (38%)
70+ 45 (41%) 40 (33%) 7 (32%) 12 (25%)
KPS 0.321
70 1 (1%) 2 (2%) 0 (0%) 1 (1%)
80 18 (16%) 10 (8%) 10 (16%) 7 (9%)
90 75 (69%) 96 (79%) 41 (66%) 61 (77%)
100 15 (14%) 13 (11%) 11 (18%) 10 (13%)
PSAb 0.251
Median (lg/L) 16.4 12.8 15.4 12.4
Range (lg/L) 1.2–262.8 0.6–125.0 1.2–111.0 1.3–125.0
PSA group 0.031
610 33 (30%) 37 (31%) 18 (29%) 24 (30%)
10.1–20 31 (28%) 47 (39%) 18 (29%) 37 (47%)
>20 45 (41%) 37 (31%) 26 (42%) 18 (23%)
Gleason score 0.633
<7 48 (44%) 50 (41%) 28 (45%) 30 (38%)
=7 46 (42%) 56 (46%) 25 (40%) 38 (48%)
>7 15 (14%) 15 (12%) 9 (15%) 11 (14%)
T stage 0.944
T1 8 (7%) 15 (12%) 6 (10%) 10 (13%)
T2 31 (28%) 32 (26%) 16 (26%) 21 (27%)
T3 64 (59%) 64 (53%) 37 (60%) 44 (56%)
T4 6 (6%) 10 (8%) 3 (5%) 4 (5%)
Risk group 0.817
Intermediate 58 (53%) 67 (55%) 34 (55%) 46 (58%)
High 51 (47%) 54 (45%) 28 (45%) 33 (42%)
CADc 36 (33%) 41 (34%) 20 (32%) 22 (28%) 0.702
Diabetes 11 (10%) 10 (8%) 3 (5%) 3 (4%) 1.000
Initial EF 0.804
1 54 (50%) 71 (59%) 54 (87%) 71 (90%)
2 8 (7%) 8 (7%) 8 (13%) 8 (10%)
3 11 (10%) 10 (8%) – –
4 36 (33%) 32 (26%) – –
a Data are number of patients unless otherwise stated.
b Refers to the last PSA result before the start of hormone therapy.
c CAD, coronary artery disease.
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last assessment 41 patients were living free from ED (measured at
least 90 days after end RT) with a median follow-up of 87 months
(range 4–120). The median time from end of RT to the recording of
grade 3–4 EF toxicity for those who developed ED (again measured
at least 90 days from end RT) was 10.5 months (range 3–103;
n = 100).
Twenty-nine percent of those with initial grades 1–2 (n = 141)
retained EF throughout their follow-up (pre salvage hormones if
applicable). The majority of patients developed long term EF toxic-
ity. Speciﬁcally 100 patients (71%) experienced ED (grades 3–4).
Grade 2, 3 and 4 late EF toxicity was identiﬁed in 12 (8%), 27
(19%) and 73 (52%) patients respectively.
Of those with grades 1–2 at baseline, 46%, 52%, 42%, 37% and
32%, had grades 1 or 2, within the ﬁrst year, between years 1 and
2, between years 2 and 3, between years 4 and 5 and between
years 7 and 8 following EBRT respectively.
The greatest decline was observed within the ﬁrst year of treat-
ment (Table 2) and this was shown to be statistically signiﬁcant
using Wilcoxon signed-rank test for those patients (133 out of141) for whom we had follow-up data (z = 8.2, p < 0.0001), with a
large effect size (r = 0.49). The median EF decreased from a pre-
treatment grade 1 to grade 3 within the ﬁrst year post treatment.
In the periods between 1–2, 2–3, 4–5, and 7–8 years after treat-
ment, there were signiﬁcant reductions in EF from baseline,
z = 7.56, 7.81, 7.54 and 6.31 respectively, p < 0.0001 in each case,
with medium to large effect sizes (r = 0.46, 0.48, 0.49 and 0.44
respectively). The median EF decreased from a pre-treatment grade
1 to grade 2 in the period between years 1 and 2 and to grades 3, 3,
and 3.5 for the periods between years 2–3, 4–5, and 7–8.
The worst EF grade did not change signiﬁcantly between the EF
assessment within 1 year of RT and that between years 1 and 2
(z = 1.3, p = 0.18). The increase for the 8-month arm from 39%
to 51% was not statistically signiﬁcant (Table 2).
The Friedman test revealed no signiﬁcant difference in the
worst EF grade across the three early post-treatment time points
i.e. within 1 year, between years 1–2 and 2–3. v2 (2,
n = 113) = 3.19, p = 0.203. However, a Friedman test indicated that
there was a statistically signiﬁcant difference in worst EF grade
across the ﬁve post-treatment time points i.e. within 1 year,
Table 2
Randomised trial ICORG 97-01. Four month neo-adjuvant hormone therapy (arm 1) versus 8 months (arm 2) prior to radiation. N0 M0. Post-treatment erectile function (EF)
outcomes by arm.a




Mann–Whitney or v2 test
p
Follow-up from end of RT to last EF assessment (months)
Range 17–141 4–132
Median 91.8 79.8 0.084
Status as at October 2010 0.389
Alive recent contact 50 (81%) 57 (72%)
Alive last contact pre 2006 0 (0%) 1 (1%)
Dead 12 (19%) 21 (27%)
Biochemical or clinical failure 0.912
Yes 26 (42%) 35 (44%)
No 36 (58%) 44 (56%)
Worst EF grade during follow-up (pre-SHT) 0.968
1 12 (19%) 17 (21%)
2 6 (10%) 6 (8%)
3 12 (19%) 15 (19%)
4 32 (52%) 41 (52%)
EF grades 1–2 (No. assessed) (32–59) (33–76)
Within 1st year after end of RT (133) 31 (54%) 30 (39%) 0.125
1–2 Years after end of RT (128) 32 (54%) 35 (51%) 0.827
2–3 Years after end of RT (120) 27 (49%) 24 (37%) 0.247
4–5 Years after end of RT (99) 19 (42%) 18 (33%) 0.483
7–8 Years after end of RT (65) 13 (41%) 8 (24%) 0.251
EF at last follow-up 0.438
1 18 (29%) 17 (21%)
2 5 (8%) 3 (4%)
3 10 (16%) 17 (22%)
4 29 (47%) 42 (53%)
EF at last follow-up 0.186
1–2 23 (37%) 20 (25%)
3–4 39 (63%) 59 (75%)
Post-treatment EF aid (ever) 0.539
Yes 17 (27%) 17 (22%)
No 45 (73%) 62 (78%)
a Data are number of patients unless otherwise stated.
100 Erectile function and duration of neo-adjuvant hormone therapy for prostate cancerbetween years 1–2, 2–3, 4–5 and 7–8. v2 (4, n = 59) = 25.05,
p < 0.0001. When examined further by treatment group, only the
8-month arm showed a statistically signiﬁcant difference.
EF grades 1–2 survival curves are shown in Fig. 2. Survival
curves are curtailed at 72 months when the cumulative probability
of EF survival i.e. the probability of maintaining EF sufﬁcient for
penetration, was 28% and 22% in arms 1 and 2, respectively, when
11 and 9 cases, respectively, were remaining. The median time to
grade 3–4 EF toxicity was 14.6 months, 17.6 months in arm 1
and 13.7 in arm 2. Treatment comparisons with respect to EF are
listed in Table 3 as 5 and 7-year estimates. EF survival did not differ
signiﬁcantly between arms overall or at 5 or 7 years. The estimated
EF grades 1–2 survival rates at 5 years were 28% (22–34) for pa-
tients receiving 4 months ADT versus 24% (19–30) for those receiv-
ing 8 months ADT (95% CI for difference:0.12 to 0.20). Seven-year
EF survival was 23% (17–29) in the 4 month group and 22% (16–27)
in the 8 month group (95% CI for difference: 0.15 to 0.17). When
adjusted for the risk strata there were no statistically signiﬁcant
differences between the two arms for EF survival.
Other factors
Using Cox proportional hazards models, risk factors were eval-
uated as potential prognostic indicators by univariate analysis. The
inﬂuences of risk group, age group, CAD/HTN, a history of diabetes,
duration of neo-adjuvant hormones and salvage hormone therapy
on EF grades 1–2 survival were assessed. Only age group (p = 0.04)
was a predictor of ED. The estimated hazard or risk of ED increases
by 1.9 times for the oldest (70+) age group compared to the
youngest (<65); increased HR 1.9; 95% CI = 1.0–3.5 p = 0.035. Theestimated hazard or risk of ED increases by 1.6 times for the 65–
69 years age group; increased HR 1.6; 95% CI = 1.0–2.5 p = 0.03.
The youngest patients took longer to become grade 3–4
(30 months versus 14.7 months for the oldest age group).
We also performed a subgroup analysis for patients who did
not receive salvage hormone therapy: Eighty-six patients (61%)
with initial EF grades 1–2 did not require salvage hormone ther-
apy for biochemical or clinical failure. Of these, 42% retained EF
during the ﬁrst year, 57% within years 1–2, 46% within years 2–
3, 45% within years 4–5, and 44% within years 7–8 post RT.
Median time to ED was 15.4 months in the 4-month arm and
13.2 months in the 8-month arm (p = 0.626).Discussion
There is a paucity of detailed analysis of the effects on EF of
neo-adjuvant androgen deprivation therapy and external beam
radiotherapy for localised prostate cancer in the literature. Direct
comparison of data on ED after EBRT with/without NAD is extre-
mely difﬁcult due to the large variability in factors such as
radiotherapy techniques, duration of hormone therapy and
methods of data collection. Standard deﬁnitions of EF/potency
imply both a capacity and opportunity for sexual activity. In this
study, our aim was to analyse the data in order to counsel pa-
tients in a real and meaningful way about their projected EF
when recommending a course of neo-adjuvant hormone therapy
in combination with external beam radiotherapy.
Overall in our study 61% of patients had EF grade 1–2 at the out-
set. When compared to previously published data we see that this
Cen Obs N Number of patients at risk 
18 44 62 36 23 17 14 12 11 
23 56 79 37 25 18 16 13   9 
Fig. 2. Survival of erectile function grades 1–2 (sufﬁcient for penetration) for
patients randomly assigned to 4 months neo-adjuvant hormone therapy (4; n = 62)
versus 8 months (8; n = 79), prior to radiation (median duration of follow-up:
87 months).
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by Chen et al. [13] and one of 67% reported by Beard et al. [14] but
is higher than the ﬁndings of the larger study of 800 patients by the
Trans-Tasman Radiation Oncology Group [15] with rates of 33–38%
at baseline.
The median follow-up time, for the 141 patients with EF
grades 1–2 at baseline, was 86 months. This represents a much
longer follow up time than comparable studies thus providing
us with some of the most detailed long term data on the topic.
The most signiﬁcant decrease in EF grade was noted within
the ﬁrst year with only 54% and 39% of patients in the 4 and
8 month arms retaining EF grades 1–2 at this time. The RTOG
9408 study noted a 48% potency rate at baseline with a decrease
to 21% at year 1 in the ADT + EBRT arm versus baseline of 54%
decreasing to 31% in EBRT alone arm [16] Other studies support
the ﬁnding that during the ﬁrst year after treatment the most
remarkable decreases in potency grade occur. A meta-analysisTable 3
Treatment comparisons with respect to erectile function (EF) grades 1–2 survival.
4-Months
Inter High Total
Median FU (range) months 92 (17–
N 34 28 62
No. of events 23 21 44
Median EF grades 1–2 survival
(months)
30.0 13.5 17.6
Cumulative prob of surv at 5 years + SE 33% (24–41) 23% (14–32) 28% (22
Cumulative prob of surv at 7 years + SE 23% (16–30) 15% (7–24) 23% (17
a Adjusted for risk.
b Not adjusted for risk FU, follow-up from end of RT to the last EF assessment; SE, staby Robinson et al. [3] found the probability of maintaining EF
at one year after treatment with EBRT alone to be 0.55, and
0.52 at 2 years, thus illustrating the signiﬁcance of the ﬁrst year.
Siglin et al. [17] noted a maximal decrease in EF within the ﬁrst
24 months after EBRT but no signiﬁcant changes thereafter.
Physiologically we would expect continued development of late
effects for many years following radiotherapy and our ﬁnding
that for the most part, EF grades decreased progressively, with
the lowest scores at the latest follow-up time ﬁts with this
hypothesis. However, the combination of NAD and EBRT need
not necessarily signal the end of sexual activity for all patients
as, based on our ﬁgures, a man who receives 4 months of ADT
has a 28% chance of retaining erectile function at 5 years. This
ﬁgure is in keeping with an analysis of 544 potent men by Zelef-
sky et al. [18] which showed that the 5 year actuarial risk of
impotence among patients treated with 3-months NAD and EBRT
was 69% i.e. 31% chance of retaining erectile function.
Intuitively one would expect that a shorter duration of andro-
gen deprivation when used in combination with EBRT would re-
sult in less sexual toxicity, however, we failed to identify a
statistically signiﬁcant difference in EF toxicity between 4 and
8 months of NAD before RT. The difference at last follow up of
37% retaining EF in the 4-month arm compared with 25% of
those in the 8-month arm was not statistically signiﬁcant and
in addition was not supported by the 5 and 7 year EF survival
rates in both arms. In the TTROG study it was noted that one
year post radiotherapy those who received 3 months ADT had
a potency rate of 12.1% in comparison to 14.2% for those receiv-
ing 6 months ADT.
In keeping with published data, we found that age group was
a signiﬁcant predictor of post treatment EF. Being in the oldest
age group increased the hazard/probability of ED. Risk group,
CAD/HTN, a history of diabetes (n = 6) and treatment arm did
not predict post-treatment ED. However numbers were small
and whilst such co-morbidity data was documented at baseline
in all patients, it was not routinely reviewed at later time points
and so it is possible that some patients developed conditions
such as diabetes during the follow up period. Lamb et al. and
Mantz et al. [15,19] similarly noted that patient age was a major
factor in predicting sexual activity post radiation treatment. In
addition, Mantz et al. identiﬁed diabetes, CAD and androgen
deprivation therapy as signiﬁcant predictors of post EBRT sexual
dysfunction.
The subset analysis of patients with initial EF grade 1–2 who did
not require salvage hormone therapy for biochemical or clinical
failure showed that these patients retained sexual function for
similar lengths of time to those in the main analysis (median:
14.3 and 14.6 months respectively).
Randomised trials have shown a PSA PFS advantage when doses
higher than used in this trial were used [20,21]. However sexual
functionoutcomes arenotwidely reported. It hasbeenhypothesised
that higher doses of radiation will negate the need for androgen8-Months Log Rank v2 test
(total versus totala)
Inter High Total v 2; p
141) 80 (4–132) 0.084
46 33 79
34 22 56 0.413; 0.521a
13.8 14.3 13.7 0.452; 0.501b
–34) 23% (16–30) 26% (17–35) 24% (19–30)
–29) 18% (11–25) 26% (7–24) 22% (16–27)
ndard error.
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fects. Considering this hypothesis, Van der Wielen et al. [22] did
not ﬁnd a signiﬁcant difference in ED up to three years post EBRT
in 114 initially sexually active men treated with either 68 or
78 Gy. In contrast Zelefsky et al. [18] noted a 5-year actuarial likeli-
hood of impotence among patients with pre-therapy potency who
receivedP75.6 Gy of 68%, compared with 52% for those treated to
670.2 Gy (p < 0.001). The on-goingRTOG0815 trial [23],which aims
to deﬁne the magnitude of beneﬁt for adding ADT to dose-escalated
RT, may address these issues by comparing treatment arms for dif-
ferences in prostate cancer health related quality of life outcomes
including sexual complications.
There are several limitations to our study. Sexual function is a
difﬁcult parameter to assess in a population of older men, as fac-
tors other than ED are sometimes responsible for patients being
sexually inactive. For this reason, it would have been preferable
to have recorded information on whether or not the patient was
sexually active (as opposed to sexually potent) at baseline and dur-
ing follow up. In addition testosterone levels were not measured
routinely and so the importance of testosterone recovery could
not be assessed. Another possible area of interest that was not
examined (data were not entered into the database) was dose to
the penile structures. Notably a review by Van der Wielen [24]
on ED after radiotherapy for prostate cancer and radiation dose
to the penile structures found that published reports on the topic
are contradictory and particularly, in relation to the penile bulb,
studies with more patients tend not to ﬁnd any correlation. In a
separate review of dose volume effects of radiotherapy in the pel-
vis, Fiorino et al. [25] acknowledged that, whilst dose volume con-
straints to the penile bulb have been proposed, this remains a
controversial topic. They commented that there is ‘‘lack of evi-
dence based knowledge on the anatomical regions involved in
the expression of erectile dysfunction’’ hence leading to difﬁculties
delineating the appropriate organ at risk.
Conclusion
This randomised trial provides us with unique long term follow
up data. When counselling men about EF prior to a course of neo-
adjuvant androgen deprivation therapy in combination with exter-
nal beam radiotherapy for localised prostate cancer we must
emphasise that the ﬁrst year post treatment poses the greatest risk
to sexual function and a continued decline may be expected. Age is
also a consideration with younger men having a greater chance of
retaining erectile function. However, 26% of men can expect to re-
tain sexual function at 5 years.
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